Helena K. Grannis’ practice focuses on corporate and financial transactions, particularly capital market transactions, disclosure and corporate governance.

Her work spans numerous industries, including airlines, aviation and aerospace; automotive; consumer products and retail; banking and financial institutions; and pharmaceuticals and biotechnology.

Helena joined the firm in 2000 and became counsel in 2012.

Notable Experience

  • Regularly advises clients on corporate governance and disclosure matters, including for a multinational, conglomerate company, pharmaceutical companies, financial institutions, and food service companies.

  • A multinational conglomerate company in connection with the spin-off, over $7.5 billion of notes offerings and a concurrent abbreviated cash tender offer, and over €7 billion in Eurobond offerings.

  • Cushman & Wakefield and its principal shareholders in the company’s $765 million initial public offering and multiple follow-on offerings and its inaugural secured notes offering.

  • TPG Specialty Lending in its $112 million initial public offering and concurrent $50 million private placement, in an approximately $74 million follow-on offering, and in over $300 million of senior and convertible notes offerings.

  • The carve-out and sale of Surgical Care Affiliates of HealthSouth to a leading private investment firm, and in its subsequent $270 million initial public offering.

  • Copa Holdings, S.A. in a $350 million offering of convertible senior notes in a private offering to qualified institutional buyers. 

  • Biomet in its proposed initial public offering and Biomet, Goldman Sachs PIA, and KKR among other financial institutions in the $13.35 billion sale of Biomet to Zimmer Holdings; and subsequent secondary sales by the consortium.

  • Hellman & Friedman as stockholders in the SEC-registered IPO of Artisan Partners Asset Management and SEC-registered secondary offerings.

  • A leading U.S. financial institution in several SEC-registered notes offerings, totaling more than $8 billion (HSBC).

  • Allergan in its $30 billion three-part offering in connection with its $70.5 billion acquisition of a pharmaceutical company; in the company’s structured accelerated share repurchase of $10 billion of outstanding shares; in its concurrent bond offering and tender offer; and in multiple bond offerings. 

  • An investment and insurance company on multiple high-profile matters, including the $2.5 billion capital investment by Allianz and the $3.3 billion capital raise to repay TARP funds. She also advised on securities regulatory, disclosure and corporate governance matters (The Hartford).

  • The underwriters, structuring agents and dealer managers in a series of capital markets transactions by AIG totaling over $10 billion.

See More

Selected Activities

  • Member, Committee on Securities Regulation, New York City Bar Association
  • Staff member, United States Senate Committee on Banking, Housing and Urban Affairs, 1995 to 1997